Alison W Rebman Selected Research

Post-Lyme Disease Syndrome

3/2022	Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: A prospective cohort study.
1/2022	Peptidylarginine Deiminase 2 Autoantibodies Are Linked to Less Severe Disease in Multiple Sclerosis and Post-treatment Lyme Disease.
10/2021	Metabolic Response in Patients With Post-treatment Lyme Disease Symptoms/Syndrome.
1/2020	Risk Factors and Outcomes of Treatment Delays in Lyme Disease: A Population-Based Retrospective Cohort Study.
1/2019	The General Symptom Questionnaire-30 (GSQ-30): A Brief Measure of Multi-System Symptom Burden in Lyme Disease.
12/2018	Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alison W Rebman Research Topics

Disease

16	Lyme Disease (Disease, Lyme) 03/2022 - 01/2012
6	Post-Lyme Disease Syndrome 03/2022 - 12/2018
5	Erythema 12/2020 - 01/2012
3	Infections 01/2018 - 12/2015
2	Exanthema (Rash) 12/2020 - 08/2012
2	Tick-Borne Diseases (Tick-Borne Disease) 12/2020 - 02/2016
2	Fatigue 01/2020 - 03/2017
2	Pain (Aches) 01/2020 - 03/2017
1	Inflammation (Inflammations) 01/2022
1	Multiple Sclerosis 01/2022
1	Neuromyelitis Optica (Devic's Disease) 01/2022
1	Neurologic Manifestations (Neurological Manifestations) 01/2021
1	Cognitive Dysfunction 03/2017
1	Chronic Disease (Chronic Diseases) 02/2016

Drug/Important Bio-Agent (IBA)

11	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 01/2012
5	AntibodiesIBA 01/2022 - 12/2015
4	Biomarkers (Surrogate Marker)IBA 10/2021 - 02/2016
2	Doxycycline (Periostat)FDA LinkGeneric 01/2019 - 03/2015
2	AntigensIBA 01/2018 - 12/2015
2	Immunoglobulin G (IgG)IBA 12/2015 - 08/2012
1	mirfentanilIBA 01/2022
1	Protein-Arginine DeiminasesIBA 01/2022
1	AutoantibodiesIBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	VaccinesIBA 12/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Blood Proteins (Serum Proteins)IBA 01/2020
1	Staphylococcal Protein A (Protein A)IBA 12/2018
1	ChemokinesIBA 09/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 02/2016
1	Peptides (Polypeptides)IBA 12/2015
1	Membrane Proteins (Integral Membrane Proteins)IBA 12/2015
1	Immunoglobulin M (IgM)IBA 12/2015
1	DNA (Deoxyribonucleic Acid)IBA 01/2012

Therapy/Procedure

5	Aftercare (After-Treatment) 03/2022 - 02/2016
5	Therapeutics 01/2019 - 01/2012
1	Ambulatory Care (Outpatient Care) 01/2020
1	Treatment Delay 01/2020
1	Time-to-Treatment 01/2020